• Explore /
  • Poster
  • / Preliminary safety data from KEYNOTE-059: pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.

Preliminary safety data from KEYNOTE-059: pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer.

Abstract Poster

Authors

null

Charles S. Fuchs

Dana-Farber Cancer Institute, Boston, MA

Charles S. Fuchs , Atsushi Ohtsu , Josep Tabernero , Eric Van Cutsem , Jiang Dian Wang , Baohoang Lam , Rita Dalal , Minori Koshiji , Yung-Jue Bang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02335411

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4037)

DOI

10.1200/JCO.2016.34.15_suppl.4037

Abstract #

4037

Poster Bd #

29

Abstract Disclosures

Similar Posters

First Author: Charles S. Fuchs

First Author: Yelena Y. Janjigian

First Author: Yung-Jue Bang

First Author: Zev A. Wainberg